Estrogen stimulation of COX-2-derived PGI2 confers atheroprotection

Trends in Endocrinology and Metabolism

Volumn 16, Issue 5, 2005, Pages 199-201

  Shah, Bukhtiar H ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PROSTACYCLIN; ROFECOXIB; THROMBOXANE A2; VALDECOXIB; VASOCONSTRICTOR AGENT;

CARDIOVASCULAR FUNCTION; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; ENZYME ACTIVATION; ESTROGEN SYNTHESIS; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; STOMACH ULCER; STROKE;

EID: 20744460257     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2005.05.008     Document Type: Short Survey

References (16)

1. A.N. Hata, and R.M. Breyer Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation Pharmacol. Ther. 103 2004 147 166
2. G.A. FitzGerald COX-2 and beyond: approaches to prostaglandin inhibition in human disease Nat. Rev. Drug Discov. 2 2003 879 890
3. K.M. Egan COX-2-derived prostacyclin confers atheroprotection on female mice Science 306 2004 1954 1957
4. E. Justice, and D.M. Carruthers Cardiovascular risk and COX-2 inhibition in rheumatological practice J. Hum. Hypertens. 19 2005 1 5
5. D.H. Solomon Relationship between COX-2 specific inhibitors and hypertension Hypertension 44 2004 140 145
6. C. Bombardier Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group N. Engl. J. Med. 343 2000 1520 1530
7. D.J. Graham Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study Lancet 365 2005 475 481
8. R.S. Bresalier Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial N. Engl. J. Med. 352 2005 1092 1102
9. Diaz-Cruz, E.S. et al. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J. Clin. Endocrinol. Metab. (in press)
10. E.T. Hawk Prevention and therapy of colorectal cancer Med. Clin. North Am. 89 2005 85 110
11. S. Bunting The prostacyclin-thromboxane A2 balance: pathophysiological and therapeutic implications Br. Med. Bull. 39 1983 271 276
12. Y. Cheng Role of prostacyclin in the cardiovascular response to thromboxane A2 Science 296 2002 539 541
13. K.M. Egan Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism Circulation 111 2005 334 342
14. A.O. Mueck, and H. Seeger Estrogens acting as cardiovascular agents: direct vascular actions Curr. Med. Chem. Cardiovasc. Hematol. Agents 2 2004 35 42
15. D.P. McDonnell The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer Clin. Cancer Res. 11 2005 871s 877s
16. B. Arun, and P. Goss The role of COX-2 inhibition in breast cancer treatment and prevention Semin. Oncol. 31 2004 22 29